Plasmablastic Myeloma: Case Report

Zriba, Sami; Kacem, Karima; Ghedira, H.; Doghri, Raoudha; Marwa, B; Stambouli, Hela; Sadek, Fehmi M

doi:10.21474/ijar01/10836

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 9 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment for both the malignancies as well as prognosis is highly different and it requires a meticulous clinical, morphological and flowcytometric analysis to differentiate between the two [8]. Colomo et al in their study concluded that CD56 was a specific for plasma cell myelomas [9].…”

Section: Discussionmentioning

confidence: 99%

Plasmablastic Multiple Myeloma Masquerading Leukemia in an Immunocompetent Patient

Anand¹,

Singh²,

Agarwal³

2020

J Diagn Case Rep

View full text Add to dashboard Cite

Multiple myeloma (MM) is a plasma cell neoplasm accounting for 1% of all malignancies. It is characterized by a monoclonal malignant proliferation of plasma cells accompanied by an increase in M-protein. Plasmablastic myeloma represents 5-15% of the cases of multiple myeloma. This morphology of a MM is an independent predictor of poor survival. Plasmablastic myeloma tends to have worse outcomes than other plasma cell dyscrasias. The median survival of these patients is around 1.9 years. Much of our knowledge on plasmablastic variant of MM is dependent on case reports and case series. Hence, an early identification of this aggressive variant of multiple myeloma and its differentiation from hematological malignancy like plasmablastic lymphoma is necessary for optimal patient management.

show abstract

Section: Discussionmentioning

confidence: 99%